Voyager Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
Voyager Therapeutics, Inc. (VYGR) reported Payments to Acquire Debt Securities, Available-for-sale of $333.23 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2019-02-26
- Voyager Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2017-12-31 was $97.44M, a 113.11% increase year-over-year.
- Voyager Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2016-12-31 was $45.72M, a 61.93% decline year-over-year.
- Voyager Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2016-09-30 was $54.59M, a 345.45% increase year-over-year.
- Voyager Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2015-12-31 was $120.12M.
- Voyager Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2018 was $333.23M, a 126.23% increase from fiscal 2017.
- Voyager Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2017 was $147.30M, a 31.10% increase from fiscal 2016.
- Voyager Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2016 was $112.35M, a 49.02% decline from fiscal 2015.
- Voyager Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2015 was $220.40M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2018-12-31 | $333.23M 10-K · filed 2019-02-26 | |||
| 2017-12-31 | $97.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $147.30M 10-K · filed 2019-02-26 | ||
| 2017-09-30 | $49.86M 10-Q · filed 2017-11-02 | |||
| 2016-12-31 | $45.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $100.31M derived: sum of 2 quarters · filed 2019-02-26 | $112.35M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $54.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $66.63M 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $12.04M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $120.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $132.37M derived: sum of 2 quarters · filed 2018-03-14 | $220.40M 10-K · filed 2018-03-14 | |
| 2015-09-30 | $12.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $100.28M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $88.03M 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |